Market closed
Cytosorbents/$CTSO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cytosorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Ticker
$CTSO
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
186
Website
Cytosorbents Metrics
BasicAdvanced
$49M
Market cap
-
P/E ratio
-$0.36
EPS
0.56
Beta
-
Dividend rate
Price and volume
Market cap
$49M
Beta
0.56
52-week high
$2.15
52-week low
$0.70
Average daily volume
132K
Financial strength
Current ratio
1.969
Quick ratio
1.461
Long term debt to equity
202.897
Total debt to equity
206.22
Interest coverage (TTM)
-25.19%
Management effectiveness
Return on assets (TTM)
-27.93%
Return on equity (TTM)
-118.50%
Valuation
Price to revenue (TTM)
1.236
Price to book
3.73
Price to tangible book (TTM)
3.73
Price to free cash flow (TTM)
-2.432
Growth
Revenue change (TTM)
1.80%
Earnings per share change (TTM)
-33.22%
3-year revenue growth (CAGR)
-5.23%
3-year earnings per share growth (CAGR)
-1.06%
What the Analysts think about Cytosorbents
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cytosorbents stock.
Cytosorbents Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cytosorbents Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cytosorbents News
AllArticlesVideos
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
GlobeNewsWire·2 weeks ago
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cytosorbents stock?
Cytosorbents (CTSO) has a market cap of $49M as of November 23, 2024.
What is the P/E ratio for Cytosorbents stock?
The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of November 23, 2024.
Does Cytosorbents stock pay dividends?
No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of November 23, 2024.
When is the next Cytosorbents dividend payment date?
Cytosorbents (CTSO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytosorbents?
Cytosorbents (CTSO) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.